RecruitingNot Applicable

A Feasibility Study of Mass-Based Response Drug Screening to Guide Personalized Hyperthermic Intraperitoneal Chemotherapy for High-Grade Appendiceal and Colorectal Adenocarcinoma With Peritoneal Metastasis

United States20 participantsStarted 2026-03

Plain-language summary

This study will evaluate the role of mass-based response testing (MRT) to select and deliver personalized hyperthermic intraperitoneal chemotherapy (HIPEC) regimens to patients with peritoneal metastasis (PM) from high-grade appendiceal adenocarcinomas (HGAA) and colorectal cancer (CRC).

Who can participate

Age range18 Years – 81 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Appendiceal adenocarcinoma (moderately/poorly differentiated, and/or signet ring cell tumors)
✓. Colorectal adenocarcinoma
✓. Suspected colon, small bowel, or appendiceal adenocarcinoma in setting of unknown primary

What they're measuring

Feasibility of performing MRT to select and deliver personalized HIPEC

Timeframe: at end of study, up to 12 months

Trial details

NCT IDNCT07291180

SponsorYale University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-10

Contact for this trial

Wumi Jemiseye, MPH

203-737-2073 wumi.jemiseye@yale.edu

View on ClinicalTrials.gov More Appendiceal Cancer trials